Drug intelligence / Profile preview

beta1-solanine

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral, Intraperitoneal, Intravenous

Overview

beta1-solanine is a specific solanine derivative and glycoalkaloid small molecule referenced in an in silico docking study as a potential acetylcholinesterase inhibitor for Alzheimer's disease. The available evidence in the provided source is limited to computational binding analysis against acetylcholinesterase, where beta1-solanine was evaluated alongside alpha-solanine, beta2-solanine, and rivastigmine. There is no clear evidence from the provided material that beta1-solanine is an approved medicine, clinically developed pharmaceutical candidate, or branded product, and no developer or manufacturer is identified.

Other names: beta1-solaninebeta-1-solaninebeta 1-solanine

Targets

Acetylcholinesterase

Beyond the preview

Go deeper on beta1-solanine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on beta1-solanine.

Explore the full profile